Evidence map›Paper›PMID 37987470›Full record

ArticleGeriatrics (Basel, Switzerland)2023

Prolonged COVID-19 Infection in a Patient with Complete Remission from Follicular Lymphoma with Hyperosmolar Hyperglycemic Syndrome.

Takuya Omura, Akira Katsumi, Shuji Kawashima, Masahiro Naya, Haruhiko Tokuda

Open access · goldAbstract readCase Reports
In one paragraph

Article in Geriatrics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Takuya OmuraDepartment of Endocrinology and Metabolism, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu 474-8511, Aichi, Japan.ORCID 0000-0001-5490-8653
Akira KatsumiDepartment of Hematology, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu 474-8511, Aichi, Japan.
Shuji KawashimaDepartment of Endocrinology and Metabolism, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu 474-8511, Aichi, Japan.
Masahiro NayaDepartment of Clinical Laboratory, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu 474-8511, Aichi, Japan.
Haruhiko TokudaDepartment of Endocrinology and Metabolism, National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu 474-8511, Aichi, Japan.
National Center for Geriatrics and Gerontology · JP

Funding

Japan Health Research Promotion Bureau 2020-B-09
6 · The paper itself

Abstract

An 81-year-old woman undergoing B-cell depletion therapy developed COVID-19 and a hyperglycemic hyperosmotic state. She had a history of multiple vaccinations against coronaviruses but had persistent antigen positivity. Strategies to prevent the development of COVID-19 in immunosuppressed patients have not been established. Moreover, there is no standard treatment for prolonged antigen positivity. In this case, we were able to follow IgG antibodies during the course of treatment. The absence of N-IgG antibody titer elevation despite an effective immune response triggered by the vaccine is of great interest. The impaired humoral response observed in patients with lymphoma after anti-CD20 treatment implies the need for a justified different vaccination strategy for these patients. Furthermore, negative N-IgG titers in the immunosuppressed state may serve as an indicator of resistance to therapy.

Indexed as

follicular lymphomahyperosmolar hyperglycemia syndromeprolonged COVID-19tixagevimab/cilgavimab

Identifiers

PMID37987470
PMCPMC10660512
OpenAlexW4388633676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.